According to ANVISA’s recent announcement, the new clinical data requirements apply to qualifying devices submitted for review in both cadastro and registro registration routes. The key points from the technical notefor manufacturers are: Clinical data is now required for all novel devices. Some high-risk devices for which ANVISA determines safety and effectiveness may only be demonstrated via clinical […]